|
|
Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial
Vincent Ribrag
,
Serge Koscielny
,
Jacques Bosq
,
Thibaut Leguay
,
Olivier Casasnovas
et al.
Journal articles
inserm-01419476v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Addition of lomustine to idarubicin and cytarabine improves the outcome of elderly patients with de novo acute myeloid leukemia: a report from the GOELAMS.
Arnaud Pigneux
,
Jean-Luc Harousseau
,
Francis Witz
,
Mathieu Sauvezie
,
Marie-Christine Bene
et al.
Journal articles
hal-00849638v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Evolving characteristics and outcome of secondary acute promyelocytic leukemia (APL): A prospective analysis by the French-Belgian-Swiss APL group
Thorsten Braun
,
Sophie Cereja
,
Sylvie Chevret
,
Emmanuel Raffoux
,
Marie Beaumont
et al.
Journal articles
hal-01237097v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?
Francine Garnache-Ottou
,
Chrystelle Vidal
,
Sabeha Biichlé
,
Florian Renosi
,
Eve Poret
et al.
Journal articles
hal-02442440v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Molecular classification and prognosis in younger adults with acute myeloid leukemia and intermediate-risk cytogenetics treated or not by gemtuzumab ozogamycin: Final results of the GOELAMS/FILO acute myeloid leukemia 2006-intermediate-risk trial
Anne Bouvier
,
Jean-Francois Hamel
,
Jacques Delaunay
,
Eric Delabesse
,
Pierre-Yves Dumas
et al.
Journal articles
hal-03604930v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Is Arsenic Trioxide (ATO) Required in the Treatment of Standard Risk Newly Diagnosed APL? Analysis of a Randomized Trial (APL 2006) By the French Belgian Swiss APL Group
Lionel Adès
,
Xavier Thomas
,
Agnes Cuerci-Bres
,
Raffoux Emmanuel
,
Olivier Spertini
et al.
Blood, 2015, 126 (23), pp.451
Journal articles
hal-01300812v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study
Élie Azoulay
,
Pedro Castro
,
Adel Maamar
,
Victoria Metaxa
,
Alice Gallo de Moraes
et al.
Journal articles
hal-03208127v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Maintenance therapy with alternating azacitidine and lenalidomide in elderly fit patients with poor prognosis acute myeloid leukemia: a phase II multicentre FILO trial
Mathilde Hunault-Berger
,
N. Maillard
,
C. Himberlin
,
C. Recher
,
Aline Schmidt-Tanguy
et al.
Journal articles
inserm-01814864v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Impact of body-surface area on patients' outcome in younger adults with acute myeloid leukemia
Xavier Cahu
,
Martin Carré
,
Christian Recher
,
Arnaud Pigneux
,
Mathilde Hunault-Berger
et al.
Journal articles
hal-01558818v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Addition of Lomustine (CCNU) to Induction and Post-Remission Chemotherapy for Fit Elderly AML Patients without Unfavorable Cytogenetics: Results of the Lamsa-2007 Goelams Trial
Arnaud Pigneux
,
Christian Récher
,
Marie C. Bene
,
Julien Asselineau
,
Ariane C. Mineur
et al.
Blood, 2015, 126 (23)
Journal articles
hal-01295674v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO study
Laetitia Largeaud
,
Pascale Cornillet-Lefebvre
,
Jean-François Hamel
,
Pierre-Yves Dumas
,
Naïs Prade
et al.
Journal articles
hal-03623649v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Induction-related cost of patients with acute myeloid leukaemia in France.
Virginie Nerich
,
Bruno Lioure
,
Maryline Rave
,
Christian Recher
,
Arnaud Pigneux
et al.
Journal articles
istex
hal-00849659v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|